Lupin shares rose 2% in morning trade after the company announced a key licensing and supply agreement with Czech-based Zentiva, a.s. The deal involves Lupin’s biosimilar Certolizumab Pegol, aimed at expanding its global footprint in the biosimilars segment. As of 10:16 AM, the shares were trading 1.19% higher at Rs 1,944.90.
Under the agreement, Lupin will handle development, manufacturing, and supply of the product, while Zentiva will manage commercialization across Europe and CIS countries. Zentiva will leverage its strong commercial infrastructure and regulatory expertise in those markets. Meanwhile, Lupin will retain commercialization rights for other global regions, including the U.S. and Canada. The agreement excludes markets like Australia, Japan, Brazil, the Philippines, and India.
Zentiva will make a non-refundable payment of up to $50 million to Lupin based on regulatory milestones, including an upfront fee of $10 million. Both companies will co-invest in product development, with profit-sharing arrangements in defined markets.
This strategic partnership allows Lupin to tap into Zentiva’s established reach in Europe while accelerating access to affordable biosimilar treatments globally. Zentiva, which serves over 100 million people in 30+ countries, adds significant market strength to the collaboration. The agreement is not a related-party transaction, and no promoter group entities are involved.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
